Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.41 |
| ▸ | OGFRL1 | Q5TC84 | 10/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 9/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.37 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4775136 | 0.81 | HRH3 (0.43) | HRH3KMT2AHRH1 | |
| SCHEMBL4775095 | 0.81 | HRH3 (0.41) | HRH3USP2HRH1 | |
| Trifluoroacetic Acid SCHEMBL4765701 | 0.76 | MAPT (0.48) | HRH3MEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL4765215 | 0.75 | SMN1; SMN2 (0.47) | HRH3HRH1 | |
| Trifluoroacetic Acid SCHEMBL4775257 | 0.75 | ROCK2 (0.44) | HRH3MEN1KMT2A | |
| SCHEMBL4770767 | 0.75 | HRH3 (0.42) | HRH3MEN1KMT2AHRH1 | |
| Trifluoroacetic Acid SCHEMBL4774309 | 0.75 | ABCB1 (0.50) | HRH3MEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL4769820 | 0.75 | ALDH1A1 (0.46) | HRH3USP2MEN1KMT2A | |
| SCHEMBL4775260 | 0.74 | HRH3 (0.40) | HRH3HRH1 | |
| Trifluoroacetic Acid SCHEMBL4772033 | 0.74 | MEN1 (0.44) | HRH3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713778-B1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-16 | — | — | EP | claimed |
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | GLAXO GROUP LIMITED (GB) | 2007-03-15 | — | — | US | claimed |
| EP-1713778-B1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | HRH3, HRH4, HRH1 | HRH3 1/4885OGFRL1 2530/4885OPRM1 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.